OBJECTIVE:To collect data and investigate the effects of Huangkui capsule(黄葵胶囊,HKC)on chronic kidney disease(CKD).METHODS:PubM ed,Embase,Cochrane Library,and three Chinese databases(China National Knowledge Infras...OBJECTIVE:To collect data and investigate the effects of Huangkui capsule(黄葵胶囊,HKC)on chronic kidney disease(CKD).METHODS:PubM ed,Embase,Cochrane Library,and three Chinese databases(China National Knowledge Infrastructure,Wanfang,and China Science and Technology Journal Database)were searched for articles published until October 2020.Randomized controlled trials(RCTs)of HKCs used for treating CKD were reviewed.Data were organized and analyzed using RevMan 5.3 software.RESULTS:HKC significantly lowered the blood urea nitrogen(BUN)level[mean difference(MD)=-2.26;95%confidence interval(CI),-2.91 to-1.61],serum creatinine level(MD=-17.45;95%CI,-22.29 to-12.60),and 24-h urine protein content(MD=-0.73;95%CI,-1.00 to-0.46)and improved the glomerular filtration rate(GFR)(MD=10.69;95%CI,5.57 to 15.81)and serum albumin level(MD=2.20;95%CI,0.49 to 3.90).CONCLUSIONS:Our findings show that HKC could lower the BUN level,serum creatinine level,and 24-h urine protein content.HKC also improved GFR and serum albumin levels.However,high-quality RCTs in other countries with larger sample sizes are warranted to confirm these findings.展开更多
基金Supported by the National Natural Science Foundation of China:Study on the mechanism of Yishen Qingli Huoxue formula regulating autophagy in kidney injury caused by metabolic disorder(No.81774245)the Protective Effect of Abelmoschus Manihot via Regulating NLRP3 Inflammasome—Pyroptosis on Renal Tubule Cells(No.81873259)+1 种基金the Mechanism of Tanshinone IIA Regulates Txnip/TRX-NLRP3 Inflammasome to Inhibit Pyroptosis and Protect Glomerular Endothelial Cells(No.82004107)Jiangsu Province Hospital of Chinese Medicine Hospital-level Project,Molecular Mechanism of Abelmoschus Manihot Regulating Fatty Acid Oxidation in Renal Tubule Cells and Antagonizing Renal Fibrosis(No.Y20026)。
文摘OBJECTIVE:To collect data and investigate the effects of Huangkui capsule(黄葵胶囊,HKC)on chronic kidney disease(CKD).METHODS:PubM ed,Embase,Cochrane Library,and three Chinese databases(China National Knowledge Infrastructure,Wanfang,and China Science and Technology Journal Database)were searched for articles published until October 2020.Randomized controlled trials(RCTs)of HKCs used for treating CKD were reviewed.Data were organized and analyzed using RevMan 5.3 software.RESULTS:HKC significantly lowered the blood urea nitrogen(BUN)level[mean difference(MD)=-2.26;95%confidence interval(CI),-2.91 to-1.61],serum creatinine level(MD=-17.45;95%CI,-22.29 to-12.60),and 24-h urine protein content(MD=-0.73;95%CI,-1.00 to-0.46)and improved the glomerular filtration rate(GFR)(MD=10.69;95%CI,5.57 to 15.81)and serum albumin level(MD=2.20;95%CI,0.49 to 3.90).CONCLUSIONS:Our findings show that HKC could lower the BUN level,serum creatinine level,and 24-h urine protein content.HKC also improved GFR and serum albumin levels.However,high-quality RCTs in other countries with larger sample sizes are warranted to confirm these findings.
